The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity

Cancer Immunology, Immunotherapy

Volumn 64, Issue 5, 2015, Pages 635-644

  Hess, Christian ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Armed antibody; Cancer therapy; Cytokine; Interleukin 13; Targeting

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOCYTOKINE; INTERLEUKIN 13; MONOCLONAL ANTIBODY F8 INTERLEUKIN 13 IMMUNOCYTOKINE; UNCLASSIFIED DRUG; F8 MONOCLONAL ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CANCER SIZE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHO CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; LYMPHOCYTE DEPLETION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SARCOMA; SURFACE PLASMON RESONANCE; TERATOCARCINOMA; TRANSIENT EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL LINE; CRICETULUS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FIBROSARCOMA; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CHO CELLS; CRICETULUS; DRUG DELIVERY SYSTEMS; FEMALE; FIBROSARCOMA; INTERLEUKIN-13; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; TERATOCARCINOMA;

EID: 84938418857     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1666-8     Document Type: Article

References (42)

1. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ (2003) IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J Immunol 171:5051–5063. doi:10.4049/jimmunol.171.10.5051
2. Welander CE (1987) Overview of preclinical and clinical-studies of interferon Alfa-2b in combination with cytotoxic drugs. Invest New Drug 5:S47–S59. doi:10.1007/BF00207263
3. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20:264–269. doi:10.1038/nbt0302-264
4. Hess C, Venetz D, Neri D (2014) Emerging classes of armed antibody therapeutics against cancer. Med Chem Commun 5:408–431. doi:10.1039/C3MD00360D
5. Schwager K, Hemmerle T, Aebischer D, Neri D (2013) The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 133:751–758. doi:10.1038/jid.2012.376
6. Hemmerle T, Neri D (2014) The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer 134:467–477. doi:10.1002/ijc.28359
7. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L (1994) The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis. Int J Cancer 59:612–618. doi:10.1002/ijc.2910590507
8. Borsi L, Castellani P, Allemanni G, Neri D, Zardi L (1998) Preparation of phage antibodies to the ED-A domain of human fibronectin. Exp Cell Res 240:244–251. doi:10.1006/excr.1998.3946
9. Frey K, Fiechter M, Schwager K, Belloni B, Barysch MJ, Neri D, Dummer R (2011) Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp Dermatol 20:685–688. doi:10.1111/j.1600-0625.2011.01314.x
10. Moschetta M, Pretto F, Berndt A et al (2012) Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res 72:1814–1824. doi:10.1158/0008-5472.CAN-11-1919
11. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 33:1718–1722. doi:10.1016/j.leukres.2009.06.025
12. Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, Berdel WE, Neri D (2013) Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 5:201ra118. doi: 10.1126/scitranslmed.3006221
13. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rosli C, Borsi L, Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122:2405–2413. doi:10.1002/ijc.23408
14. Pasche N, Neri D (2012) Immunocytokines: A novel class of potent armed antibodies. Drug Discov Today 17:583–590. doi:10.1016/j.drudis.2012.01.007
15. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147–159. doi:10.1038/nrd1957
16. Kontermann RE (2012) Antibody-cytokine fusion proteins. Arch Biochem Biophys 526:194–205. doi:10.1016/j.abb.2012.03.001
17. Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D (2012) The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 18:4092–4103. doi:10.1158/1078-0432.CCR-12-0282
18. Gutbrodt KL, Casi G, Neri D (2014) Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol Cancer Ther 13:1772–1776. doi:10.1158/1535-7163.MCT-14-0105
19. de Vries JE (1998) The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 102:165–169. doi:10.1016/S0091-6749(98)70080-6
20. Hancock A, Armstrong L, Gama R, Millar A (1998) Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 18:60–65. doi:10.1165/ajrcmb.18.1.2627
21. de Waal MalefytR, Abrams JS, Zurawski SM et al (1995) Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int Immunol 7:1405–1416. doi:10.1093/intimm/7.9.1405
22. Zurawski G, de Vries JE (1994) Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15:19–26. doi:10.1016/0167-5699(94)90021-3
23. Minty A, Chalon P, Derocq JM et al (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248–250. doi:10.1038/362248a0
24. Blais Y, Gingras S, Haagensen DE, Labrie F, Simard J (1996) Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol Cell Endocrinol 121:11–18. doi:10.1016/0303-7207(96)03843-9
25. Renard N, Duvert V, Banchereau J, Saeland S (1994) Interleukin-13 inhibits the proliferation of normal and leukemic human B-cell precursors. Blood 84:2253–2260
26. Serve H, Oelmann E, Herweg A et al (1996) Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res 56:3583–3588
27. Lebel-Binay S, Laguerre B, Quintin-Colonna F et al (1995) Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol 25:2340–2348. doi:10.1002/eji.1830250833
28. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L (1993) Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. J Immunol 150:1458–1470
29. Hsi LC, Kundu S, Palomo J, Xu B, Ficco R, Vogelbaum MA, Cathcart MK (2011) Silencing IL-13Ralpha2 promotes glioblastoma cell death via endogenous signaling. Mol Cancer Ther 10:1149–1160. doi:10.1158/1535-7163.MCT-10-1064
30. Gafner V, Trachsel E, Neri D (2006) An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 119:2205–2212. doi:10.1002/ijc.22101
31. Pasche N, Woytschak J, Wulhfard S, Villa A, Frey K, Neri D (2011) Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol 154:84–92. doi:10.1016/j.jbiotec.2011.04.003
32. Frey K, Zivanovic A, Schwager K, Neri D (2011) Antibody-based targeting of interferon-alpha to the tumor neovasculature: A critical evaluation. Integr Biol (Camb) 3:468–478. doi:10.1039/c0ib00099j
33. Holliger P, Prospero T, Winter G (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444–6448. doi:10.1073/pnas.90.14.6444
34. Sommavilla R, Pasche N, Trachsel E, Giovannoni L, Roesli C, Villa A, Neri D, Kaspar M (2010) Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. Protein Eng Des Sel 23:653–661. doi:10.1093/protein/gzq038
35. Hemmerle T, Probst P, Giovannoni L, Green AJ, Meyer T, Neri D (2013) The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer 109:1206–1213. doi:10.1038/bjc.2013.421
36. Hemmerle T, Doll F, Neri D (2014) Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis. Proc Natl Acad Sci USA 111:12008–12012. doi:10.1073/pnas.1402783111
37. Pretto F, Elia G, Castioni N, Neri D (2014) Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother 63:901–910. doi:10.1007/s00262-014-1562-7
38. Pedretti M, Verpelli C, Marlind J, Bertani G, Sala C, Neri D, Bello L (2010) Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer 103:827–836. doi:10.1038/sj.bjc.6605832
39. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA (2010) Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 207:651–667. doi:10.1084/jem.20091921
40. Quezada SA, Simpson TR, Peggs KS et al (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207:637–650. doi:10.1084/jem.20091918
41. Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, Zardi L, Neri D (2005) Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 116:304–313. doi:10.1002/ijc.20952
42. Hemmerle T, Neri D (2014) The dose-dependent tumor targeting of antibody-IFNgamma fusion proteins reveals an unexpected receptor-trapping mechanism in vivo. Cancer Immunol Res 2:559–567. doi:10.1158/2326-6066.CIR-13-0182